Par Drugs & Chemicals standalone net profit rises 2.43% in the June 2024 quarter

Par Drugs & Chemicals standalone net profit declines 11.79% in the December 2022 quarter

Par Drugs Standalone March 2022 Net Sales at Rs 22.08 crore, up 36.2% Y-o-Y

Par Drugs & Chemicals standalone net profit declines 0.41% in the March 2022 quarter

31 दिसंबर आने वाला है और नए साल के जश्न की तैयारियां जोरों पर हैं। इस मौके पर जहर का कारोबार करने वाले भी पूरी तरह से तैयार हो गए हैं। नशे की खेप की सप्लाई के लिए ड्रग्स के तस्कर अपना जाल बिछा चुके...

Abhinetriyon ke naam par drugs ke code, deepika matlab saanp ka dank, aaliya matlab...

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Par Drugs and Chemicals provides generic drugs. The Company is engaged in the development and manufacturing of Active Pharma Ingredients (APIs) for the domestic market, as well as for exports to international markets